In a univariate analysis, CD8+, CFRhigh group made a significant contribution to extending PFS in patients with advanced HER2-positive breast cancer (p = 0.027, hazard ratio [HR] = 0.162) (p = 0.008, HR = 0.195), respectively (Fig. 4a). The gene discussed is CD8A; the disease is breast carcinoma.